Criteria for and appropriateness of renal transplantation in elderly patients with end-stage renal disease : a literature review and position statement on behalf of the European Renal Association-European Dialysis and Transplant Association Descartes Working Group and European Renal Best Practice by Segall, Liviu et al.
ReviewCriteria for and Appropriateness of Renal
Transplantation in Elderly Patients With
End-Stage Renal Disease: A Literature
Review and Position Statement on Behalf
of the European Renal Association-European
Dialysis and Transplant Association
Descartes Working Group and European
Renal Best Practice
Liviu Segall, MD,1 Ionuţ Nistor, MD, PhD,2,3 Julio Pascual, MD, PhD,4,5,6 Istvan Mucsi, MD, PhD,7
Lluis Guirado, MD, PhD,8 Robert Higgins, MD, PhD,9 Steven Van Laecke, MD, PhD,10
Rainer Oberbauer, MD, PhD,6,11 Wim Van Biesen, MD, PhD,3,10 Daniel Abramowicz, MD, PhD,6,12
Cristina Gavrilovici, MD, PhD,13 Ken Farrington, MD, PhD,14 and Adrian Covic, MD, PhD2
Abstract:During the last 20 years, waiting lists for renal transplantation (RT) have grown significantly older. However, elderly pa-
tients (ie ≥65 years of age) are still more rarely referred or accepted to waiting lists and, if enlisted, have less chances of actually
receiving a kidney allograft, than younger counterparts. In this review, we looked at evidence for the benefits and risks of RT in
the elderly trying to answer the following questions: Should RT be advocated for elderly patients? What should be the criteria to
accept elderly patients on the waiting list for RT?What strategies might be used to increase the rate of RT in waitlisted elderly can-
didates? For selected elderly patients, RTwas shown to be superior to dialysis in terms of patient survival. Virtually all guidelines
recommend that patients should not be deemed ineligible for RT based on age alone, although a short life expectancy generally
might preclude RT. Concerning the assessment of comorbidities in the elderly, special attention should be paid to cardiac evalu-
ation and screening for malignancy. Comorbidity scores and frailty assessment scales might help the decision making on eligibility.
Psychosocial issues should also be evaluated. To overcome the scarcity of organ donors, elderly RTcandidates should be encour-
aged to consider expanded criteria donors and living donors, as alternatives to deceased standard criteria donors. It has been
demonstrated that expanded criteria donor RT in patients 60 years or older is associated with higher survival rates than remaining
on dialysis, whereas living donor RT is superior to all other options.
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e56 Transplantation ■ October 2016 ■ Volume 100 ■ Number 10 www.transplantjournal.comPatients over 65 years old are the fastest growing agegroup among the populationwith end-stage renal disease
(ESRD) worldwide.1 In the European Renal Association-
European Dialysis and Transplant Association (ERA-EDTA)
Registry Annual Report of 2012, patients aged 65 to
74 years and 75 years or older constitute 22% and 20%, re-
spectively, of the prevalent renal replacement therapy popu-
lation.2 The proportions are even higher in the United
States, with 24% and 34%, respectively.3
Several studies have shown that renal transplantation (RT)
is safe and provides better survival, compared with dialysis,
in patients of advanced age.4 However, many centers and
specialists are still reluctant to register elderly patients on
waiting lists for RT; this reluctance may often be due to bi-
ased opinions, because, unfortunately, objective selection
criteria for RT are poorly defined for this population.5 Fur-
thermore, in the context of donor shortage, the probability
for waitlisted elderly patients of actually receiving a kidney
transplant is still lower than that for younger counterparts.6
Nevertheless, another important reason for this lower trans-
plant rate in the elderly may be that incurring events (eg, in-
fections or cardiovascular complications) might alter their
transplant status, at least temporarily.
Management of elderly patients is often complex and spe-
cific evidence-based treatment guidelines are often lacking. A
European multidisciplinary initiative recently identified and
prioritized potential topics to be addressed for this popula-
tion. This joint initiative of the ERA-EDTA and the European
Union Geriatric Medicine Society prioritized the develop-
ment of guidance on benefits and risks of RT in elderly pa-
tients with ESRD as a topic of interest.7
In this review, we looked at relevant data in the literature
concerning the benefits and risks of RT in the elderly (ie, pa-
tients ≥65 years of age), trying to find answers to the
following questions:
1. Should RT be advocated for elderly patients?
2. What should be the criteria to accept elderly patients on the
waiting list for RT?
3. What strategies might be used to increase the rate of RT in
waitlisted elderly candidates?
BENEFITS OF RT COMPARED WITH DIALYSIS
IN ELDERLY ESRD PATIENTS
The superiority of RTover dialysis in terms of survival du-
ration has been suggested by several studies performed over
the last 20 years in ESRD patients, including the elderly8-17
(Table 1). However, RT recipients 70 years or older and, par-
ticularly, 80 years or older have a higher mortality risk, com-
pared with those 60 to 69 years.18
Furthermore, elderly RT recipients may also experience
better quality of life (QOL), as compared with dialysis,1 al-
though there are very few good studies in this field.19
Benedetti et al20 found that over 80% of RT recipients
60 years or older felt cheerful, independent, and healthy; they
reported that health problems were either a minor drawback
or no drawback to enjoying life, and 100% of them felt that
opting for RT was the correct decision. Rebollo et al21 re-
ported significantly better physical functioning, bodily pain,
general health, vitality, and social functioning scores in el-
derly RT patients compared with their counterparts staying
on dialysis. Humar et al22 showed that elderly RT recipientsscored higher in their general health perception, social func-
tioning, and mental health, as compared with the national
US norms.
In addition, RT in the elderly may also be cost-effective.
Laupacis et al23 found that in patients 60 years or older, the
annual cost of dialysis was 65 720 Canadian dollars ($CA),
whereas the cost of the first year after RT was $CA 63 708;
however, in year 2, the cost of RTwas only $CA 21 160.RISKS OF RT IN THE ELDERLY
Elderly RT recipients have an increased risk of infections
and cardiovascular events than younger patients.1,24
With aging, the immune system undergoes structural and
functional changes, including qualitative alterations in T cell
activation and/or quantitative differences in T cell subsets.25
This results in higher incidence and severity of infectious com-
plications in the elderly compared with younger transplant
recipients for the same degree of immunosuppression.
Meier-Kriesche et al26 reported an exponential increase in
deaths caused by infections in elderly RT patients, whereas
the increase was linear in their age-matched waitlisted coun-
terparts. The risk of death due to infection was 5-fold higher
in transplant recipients 65 years or older than in those aged
30 to 39 years.27 Kauffman et al28 showed that infection is
themost common cause of mortality in the first posttransplant
year in recipients 60 years or older. However, it should be
emphasized that the mortality risk from infections is even
higher for elderly patients who remain on dialysis.29
On the other hand, the decreased immune reactivity also
seems to be associated with a lower risk of acute rejection ep-
isodes after RT in the elderly.25 In more than 70 000 RT re-
cipients, Meier-Kriesche et al27 showed that the incidence of
acute rejection decreasedwith increasing age; in patients aged
18 to 29 years, the 6-month acute rejection rate was 28%,
compared with only 19.7% in those 65 years or older. Using
the United Network of Organ Sharing (UNOS) database,
Tullius and Milford30 found that in patients 70 years of
age, the rejection rate was 14% versus 28% in those aged
18 years. Another study31 showed an incidence of acute re-
jection of 37.6% in patients 50 to 59 years versus 22.7% in
those 60 years or older. In a group of RT recipients
70 years or older, acute rejection rates of 35% were seen
within the first 12 weeks posttransplantation, as compared
with 44% in patients aged 60 to 69 years and 45% in those
aged 40 to 54 years.32 However, the consequences of acute
rejection may be more severe in the elderly. In a study of
48 821 RT recipients,33 acute rejection was associated with
a rate of graft loss of 116 per 1000 patients in those
65 years or older, compared with only 43 per 1000 patients
in those aged 18 to 35 years, after adjustment for con-
founders like donor age, donor source, and delayed graft
function. In another study,34 the presence of acute rejection
episodes during the first 3 months posttransplant was a
strong predictor of premature death in the elderly (≥60 years),
as opposed to the control group (45-54 years).
In the long term, death-censored graft survival in the el-
derly appears to be comparable to or even better than that
in younger RT recipients. For example, in a study by Heldal
et al32 death-censored graft survival was similar among dif-
ferent age groups: 89% in elderly (≥70 years), 88% in senior
(60-69 years), and 90% in control (45-54 years) patients.
TABLE 1.
Survival studies in elderly ESRD patients on RT waiting list: RT recipients compared with patients staying on dialysis
Study Patients Main findings
Wolfe et al,
USA, 19998
228 552 patients on maintenance dialysis
(USRDS data)
Among patients who were 60-74 y of age, the cumulative survival rate
improved after the first year post-RT, with a projected increase in life
span of 4 y and a decrease in the long-term risk of death of 61%.
When this group was further subdivided into age subgroups of 60-64,
65-69, and 70-74 y, the projected increases in life span were 4.3 y,
2.8 y, and 1 y, respectively.
Ojo et al,
USA 20019
Patients registered on the UNOS RT
waiting list
Among patients≥65 y, the 5-y mortality risk in ECD recipients relative to those
who stayed on dialysis was 0.71, with a projected extra life time of 3.8 y.
Rao et al,
USA 200710
5667 RT candidates ≥70 y from the
SRTR, who were waitlisted between
1990 and 2004
Transplant recipients had a 41% lower overall risk of death compared with
waitlisted candidates remaining on dialysis, after adjustment for several
demographic and medical factors (RR, 0.59; P <0.0001). Further subgroup
analyses found that patients aged 70-74 y (RR, 0.58; 95% CI, 0.52-0.65),
as well as those older than 74 y (RR, 0.67; 95% CI, 0.53-0.86), had
improved survival with RT compared to those who stayed on dialysis.
Gill et al,
Canada, 200511
63,783 RT candidates who started dialysis
between 1995 and 2000
Among patients aged ≥70 y, the expected survival rates were 8.2 y for
those who received a kidney transplant, compared to only 4.5 y for
those remaining on dialysis.
Johnson et al,
Australia, 200012
174 consecutive patients ≥60 y of age who
were accepted on the Queensland cadaveric
RT waiting list between 1993 and 1997
There were 67 patients receiving a RT, whereas the other 107 continued to
undergo dialysis. These two groups were well matched at baseline with
respect to age, gender, body mass index, renal disease etiology, comorbid
illnesses, and dialysis duration and modality. Respective 1-, 3- and 5-y
survival rates were 92%, 62%, and 27% for the dialysis group and 98%,
95%, and 90% for the transplant group (P <0.01).
Bayat et al,
France, 201013
1495 adults starting renal replacement therapy
from 1997 to 2003 in the Lorraine region of
France, of which 994 were ≥60 y
Among the elderly, RT recipients had a 78% lower risk of death compared
with patients on dialysis (HR, 4.6; 95% CI, 2.2-9.7), after adjusting for
comorbidities, serum albumin and body mass index.
Savoye et al,
France, 200714
3001 patients ≥60 y waitlisted for RT, of which
2099 were transplanted
Patients who did not undergo RT had an adjusted risk of death 2.54 times
higher than that of transplanted patients of the same age (P<0.0001),
regardless of the type of graft. The risk was 3.78 times higher than that
for patients receiving SCD grafts (P < 0.0001) and 2.31 for patients
receiving ECD grafts (P<0.0001).
Oniscu et al,
Scotland, 200415
325 patients >60 y listed for RT 128 patients (39.4%) received a first transplant within the study period
and the remaining 197 (60.6%) continued to undergo dialysis. The RT
recipients were younger at listing (P<0.0001), spent less time on the
active waiting list (P<0.0001), and had less ischaemic heart disease
(P = 0.024) and cerebrovascular disease (P = 0.03). There was a
significantly lower risk of death (RR = 0.35, 95% CI 0.22-0.54;
P<0.0001) and a longer life expectancy after listing with a transplant
(8.17 vs 4.32 y).
Heldal et al,
Norway, 201016
286 ESRD patients ≥70 y of age waitlisted
for RT
Patients starting dialysis between 1990 and 1999 appeared to have no
survival advantage after RT (HR for death, 1.01; 95% CI, 0.58-1.75),
whereas, in contrast, a substantial long-term benefit of RT was seen
among those starting dialysis after 2000 (HR for death, 0.40; 95% CI,
0.19-0.83; P=0.014).
Lloveras et al,
Spain, 201517
Matched-pair analysis of 823 RT recipients
from elderly donors (65 y or older), compared
to 823 controls that remained on dialysis.
In all age groups, the dialysis patients had higher adjusted risk of death
than the transplanted patients. In the elderly groups, the RR was
2.20 (95% CI, 1.60-3.09) in those aged 65-69 y and 1.86 (95% CI,
1.11-3.11) in those ≥70 y
HR, hazard ratio; USRDS, United States Renal Data System.
© 2016 Wolters Kluwer Segall et al e57Based onUNOSdata, Keith et al35 and Tullius et al36 showed
that the death-censored risk of graft loss declined with each
successive decade increase in age. Molnar et al,37 in an anal-
ysis using US Scientific Registry of Transplant Recipients
(SRTR) data of 145 470 adult RT recipients, found that,
compared with patients 18 to 34 years, death-censored allo-
graft failure risk was lower in patients aged 65 to 69 yearsby 37%, 70 to 74 years by 36%, and 75 years or older
by 20%. Faravardeh et al38 reported death-censored graft
survival rates at 5, 10, and 15 years of 90.7%, 80.4%,
and 73.7%, respectively, for patients 65 years or older,
87.2%, 77.6%, and 71.5% for those 50 to 64 years,
and 79.8%, 70.3%, and 60.8% for those younger than
50 years. A possible explanation for the better graft survival
e58 Transplantation ■ October 2016 ■ Volume 100 ■ Number 10 www.transplantjournal.comin elderly patients might again be the depression of the im-
mune system associated with advanced age, as discussed
above, although selection bias could also explain this out-
come, to some extent. Furthermore, death censoring may
be misleading, as graft survival may thus appear to be better
in the elderly than in the younger patients simply because of a
shorter life duration in the former age-group.
Although randomized controlled studies are lacking, it is
conceivable that, given the immunosenescence, using lower
doses or alternative drug combinations couldminimize side ef-
fects like infection or malignancy in elderly RT patients, while
still being able to provide an adequate level of immunosup-
pression.39 A small study by Badowski et al40 showed that re-
duced immunosuppression was associated with improved
graft and patient survival in RT recipients 60 years or older.
Relatively few studies have compared patient survival be-
tween older and younger RT recipients, because older age is
undoubtedly associated with higher risk of death in all popu-
lations.4 In a study by Karim et al41 including 19 103 RT re-
cipients, with a median follow-up of 4.4 years, mortality risk
increased with age, as follows: below 50 years (5.8%), 50 to
59 years (14.2%), 60 to 69 years (22.0%), 70 to 79 years
(31.9%), and 80 years or older (45.5%). The 3 most common
causes of deaths for recipients 70 years or older were cardiac
(21.2%), infection (21.2%), and malignancy (20.2%). Similar
findings were reported by Faravardeh et al38 and Mendonça
et al.31 Surprisingly, however, Hatamizadeh et al42 found a
75% and 92% lower death risk in RT recipients than in the
general population, among individuals aged 65 to 75 years
and 75 years or older, respectively. Part of the explanation of
this phenomenon might be the presence of selection bias,
where older patients selected for RTmay be relatively healthier
compared to age-matched non-ESRD individuals.4TRENDS AND CURRENT PRACTICES IN
WAITLISTING FOR RTAND ALLOCATION OF KIDNEY
ALLOGRAFTS TO ELDERLY ESRD PATIENTS
Over the last decades, the emerging evidence of the benefits
and safety of RT in the elderly, as well as the ageing of the
overall ESRD population, has led to waiting lists for RT
growing significantly older in many countries, with the larg-
est absolute and relative increase in the 65 years or older
age group.43 In the United States between 1997 and 2014,
whereas the waiting list for RT increased from 30 000 to
more than 100 000 candidates, the proportion of candi-
dates 65 years or older has grown from 7% to over
21%.44 In France, this proportion increased from 2.4%
in 1998 to 11.7% in 2011, with individuals 70 years or
older, representing almost half of this elderly group.45
However, although the numbers of elderly on waiting lists
has increased, the percentage of waitlisted patients among
those with ESRD continues to decrease with advancing
age.25 For example, in the United States, the relative propor-
tion of patients waitlisted for RT decreases from 21% among
ESRD patients aged 18 to 39 years to only 3.4% among
those 70 years or older and 0.5% among those 80 years
or older.46 In France, the percentages of ESRD patients
waitlisted for RT before dialysis initiation and after 5 years
on dialysis are 11.2% and 66%, respectively, among individ-
uals younger than 60 years, but only 3.4% and 26.8%
among those 60 to 69 years and as low as 0.2% and 1.6%among those 70 years or older.47 Bayat et al48 analyzed data
of incident patients aged 18 to 80 years in 11 French regions,
who started dialysis between 2006 and 2008. Compared
with patients aged l8 to 39 years, those 70 years or older were
found to be almost twice less likely to be placed on the
waiting list, after adjustment for other patient-related and
region-related factors.
In a recent systematic review, Tong et al49 showed that
there is significant variability among nephrologists in consid-
ering RT for elderly patients, with the percentage of those
who recommend it to ESRD patients 60 years or older rang-
ing from 10% to 59%. Low rates of waitlisting for the elderly
can be explained by increasing comorbidity in this popula-
tion.50 However, some studies suggest that elderly patients
are often not listed, despite having no formal contraindica-
tions.25 Another aspect of the inequity, as shown in a study
by Salter et al51 is that discussions on RT are not maintained
with patients 65 years or older (44% vs 75% in the younger
age groups). Other reasons for not listing the elderly, as sug-
gested by Knoll,52 could be that (a) patients may not see
themselves as potential candidates and, therefore, decline this
option; (b) physicians may feel that they would “displace” a
kidney from a younger potential recipient; and (c) unlike kid-
ney allocation, which is generally governed by stronger over-
sight, referral for waitlisting is largely at the discretion of
referring physicians.52 Misconceptions regarding the criteria
for RT could prevent early referral to a transplant centre,
leading to longer time spent on dialysis by the elderly.1
Regarding the RTallocation practices, in the United States,
the probability for elderly candidates of actually receiving a
kidney transplant has steadily increased during the last de-
cades. The proportion of patients 65 years or older among
those living with a renal transplant has grown from 3.8% in
1990 to 23.3% in 2012.6 The chance of getting an RTwithin
3 years is still slightly lower in the elderly (36%), as compared
with the youngest population (44%); however, the mortality
risk while waiting is, not surprisingly, much higher in the for-
mer (16.9% vs 3.4%), which highlights the interest in increas-
ing the RT rate in this age group.6 The trends are similar in
Europe. Data from Eurotransplant indicate that the propor-
tion of deceased donor (DD) RT recipients among candidates
65 years or older increased from 3.6% in 1991 to 19.7% in
2007.43 In Denmark, for example, the group 60 years or older
accounted for 18% of prevalent RT patients in 2000 and has
increased to 30% in 2012.6 However, the rate of RT still re-
mains lower in the elderly than in younger candidates. The
United KingdomRenal Registry 2013 data show that the ratio
between the number of transplants and the number of active
patients on the waiting list in different age groups from 35 to
70 years or older decreases from 0.57 to 0.40. In France, the
probability of receiving a kidney transplant after 5 years on
dialysis is 58.6% among patients younger than 60 years of
age, but only 21.6% among those 60 to 69 years and 1.3%
among those 70 years or older.47EVALUATIONOF ELDERLY PATIENTSASPOTENTIAL
CANDIDATES FOR RT: RECOMMENDATIONS
FROM AVAILABLE GUIDELINES
Practice guidelines from major medical societies state that
age alone should not be a reason to withhold waitlisting.52
In fact, due to laws that prohibit age discrimination in
© 2016 Wolters Kluwer Segall et al e59the delivery of healthcare services, age-based transplant
allocation is illegal in many countries.
A few years ago, Batabyal et al53 performed a systematic
review of clinical practice guidelines on waitlisting for RT, in-
cluding 15 such guidelines published from 2001 to 2011. Six
guidelines54-60 recommended that patients should not be
deemed ineligible based on age alone, but that age-related co-
morbidities, however, could be considered a relative contra-
indication to RT. For example, the UK Renal Association
guidelines state that “age is not a contraindication to trans-
plantation, but age-related comorbidity is an important
limiting factor,”54 whereas the American Society of Trans-
plantation guidelines maintain that “there should be no
absolute upper age limit for excluding patients whose over-
all health and life situation suggest that transplantation
will be beneficial.”55Only 1 guideline61 recommended exclu-
sion of patients 65 years or older and proposed that patients
aged 55 to 65 years be evaluated individually, whereas an-
other guideline62 stated that candidates 70 years or older
may be waitlisted, although no clear evidence was available
to support improved outcomes.
Almost all guidelines recommended that patients with a re-
duced life expectancy should not be waitlisted, rather than
defined a specific age cutoff.53 However, it has been acknowl-
edged that this principle is difficult to interpret and apply in
clinical practice, because assessment for waitlisting involves
complex decisions based on multiple factors and because we
do not actually possess reliable tools to accurately estimate
survival duration. Three guidelines61,63,64 recommended a
minimum life expectancy of 5 years posttransplantation to
be considered forRT.One consensus statement60 declared that
patients with “an anticipated likelihood of less than 80%
chance of surviving a minimum of 5 years after transplanta-
tion” should be excluded. An anticipated survival rate of less
than 2 years was an absolute contraindication in 1 guideline,58
because “RTdoes not offer any advantage andmay instead ac-
celerate the death.” Three guidelines made qualitative recom-
mendations, that is, to exclude patients with a “short life
expectancy,”57 who were “predicted to have their lives short-
ened by transplant or experience worsening QOL,”54 or
who did not have “reasonable probability of surviving beyond
current waiting times.”56
For elderly transplant candidates, careful selection based
on thorough medical and psychosocial evaluation is recom-
mended in most studies.19 As shown by Kauffman et al,28 el-
derly patients with significant comorbidities may experience
high mortality rates early post-RT, thus drawing no survival
benefit from RT as compared with staying on dialysis. How-
ever, no clear guidelines on the criteria to use for selecting el-
derly candidates for RT are currently available.5 Although
many guidelines recommend that elderly patients should be
screened more aggressively for cardiovascular disease and
cancer, they do not provide specific criteria to determine
which patients may be suitable candidates. In addition to in-
vestigations for comorbidity, some authors suggest that el-
derly candidates should also be screened for frailty and
adherence to prescriptions, because each of these factors
can put RT recipients at risk of death or graft failure.5
Evaluation of elderly patients basically has the same objec-
tives and uses the same methods as for all RT candidates.
This includes assessment of surgical and vascular suitability,
cardiovascular tolerance to stress, malignancy, nutritionalstatus, serologic suitability, behavioral and medication com-
pliance, psychosocial and financial status.65 Such assess-
ments need to be repeated periodically in all waitlisted
patients, but probably more frequently in high-risk individ-
uals, such as the elderly.66 The purpose of the evaluation is
to identify contraindications for RT and address and correct
medical and psychological conditions that may affect trans-
plant outcomes. This evaluation commonly involves several
investigations, as shown, for example, in Table 2.62
Screening for Cardiovascular Disease and Cancer
Patients with chronic kidney disease and ESRD, in general,
have a high prevalence of cardiovascular diseases.62 These, in
fact, represent one the most common causes of mortality in
RT recipients, with highest rates in the peritransplantation
period.67 In RT candidates, older age is considered a high-
risk factor for cardiovascular events perioperatively and later
post-RT.59 Therefore, potential RT recipients—and particu-
larly the elderly—should have a careful evaluation of cardio-
vascular comorbidity. Assessment for cardiovascular disease
includes history taking, physical examination, and ECG for
all patients; abnormal results warrant further cardiac evalua-
tion.62 In addition, for asymptomatic patients 60 years or
older, some guidelines recommend noninvasive stress testing,
although they acknowledge that there is little or no evidence
to support this recommendation. The 2012 scientific statement
from the American Heart Association and the American
College of Cardiology Foundation concerning cardiac dis-
ease evaluation and management among RT candidates67
suggests that noninvasive stress testing may be considered
in patients 60 years or olderwith no active cardiac conditions
who also have at least 2 other risk factors for coronary artery
disease, including diabetes, prior cardiovascular disease,
more than 1 year on dialysis, left ventricular hypertrophy,
smoking, hypertension, and dyslipidemia (class IIb; level of
evidence C). The statement does not indicate any particular
technique(s) to be used for noninvasive testing nor the optimal
frequency for repeat testing. The ERA-EDTA guidelines59 rec-
ommend performing a standard exercise tolerance test and
cardiac ultrasound in asymptomatic high-risk patients, includ-
ing those with older age, diabetes, and history of cardiovascu-
lar disease (grade 1C). Further investigation with noninvasive
stress imaging (dobutamine stress echocardiography or myo-
cardial perfusion scintigraphy) is recommended only in those
with a positive or inconclusive exercise tolerance test (1C). In
those with a positive test for ischemia, coronary angiography
is subsequently indicated (1D).
Cancer is also very frequent in elderly dialysis pa-
tients.68 European59 and US guidelines55 maintain that
age-appropriate screening for malignancy as recommended
for the general population should also be applied to RTcandi-
dates, in the absence of specific guidelines for these patients.
This usually includes colonoscopy in patients 50 years or
older, mammogram in women 40 years or older, and serum
immunoelectrophoresis in patients older than 60 years, as
shown in Table 2.62
Charlson Comorbidity Index and Other Mortality Risk
Prediction Scores
Several comorbidity scores have been proposed to predict
posttransplantation mortality in RT candidates, which might
be used to guide decision-making for RT eligibility.
TABLE 2.
General evaluation of kidney transplant candidates62
(1) Comprehensive history and physical examination, with emphasis on:
(a) Documentation of the cause of renal disease and assessment of the
risk of recurrence in the transplanted kidney
(b) Family history, especially kidney disease, hypertension, and diabetes
(c) Evidence of coronary heart disease, cerebrovascular disease, and
peripheral vascular disease
(d) Evidence of defects in coagulation
(e) Evidence of abnormalities of the urinary tract and bladder
(f ) Financial evaluation to assess ability to afford transplant medications
(g) Psychosocial evaluation
(h) Sensitization risks, including a history of blood or platelet transfusions,
pregnancies, abortions, and previous transplants
(i) In retransplantation candidates, a detailed history of the prior transplantation
courses and cause of graft loss, medication compliance, and previous
transplant complications
(2) General laboratory tests:
(a) Blood type
(b) Complete blood count and comprehensive metabolic panel
(c) PT and PTT
(d) Serological tests for: viral hepatitis, VDRL, cytomegalovirus, and so on
(e) Tissue typing for HLA and PRA
(f ) ECG
(g) Chest X-ray and lung function testing
(h) Renal ultrasound for those on dialysis therapy for more than 5 y in
patients without recent imaging
(3) Particular laboratory tests, as indicated:
(a) PPD test in those with a history of exposure to tuberculosis, prior
residence in an endemic area, or chest X-ray suspicious of tuberculosis
(b) Colonoscopy in patients older than 50 y
(c) Gynecological evaluation, including Papanicolaou smear in women of
childbearing age
(d) Mammogram in women older than 40 y
(e) Serum immunoelectrophoresis in patients older than 60 y and those
with unexplained renal failure and anemia
(f ) Stress test, echocardiogram, and coronary angiogram
(g) Doppler studies of iliac and lower-extremity vessels or other imaging
study may be performed in patients with symptoms and signs
suggestive of peripheral vascular disease to evaluate the feasibility
of allograft placement
(h) Detailed coagulation study in those with history of deep venous
thrombosis, spontaneous abortion, recurrent clotting of a dialysis
fistula or graft, or bleeding tendency
(i) Toxoplasmosis, coccidioidomycosis, and histoplasmosis titers in
residents of endemic areas
PT, prothrombin time; PTT, partial thromboplastin time; VDRL, venereal disease research laboratory;
PPD, purified protein derivative; PRA, panel-reactive antibody; ECG, electrocardiogram
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used scoring system for comorbidities in research and clinical
practice. It assesses comorbidity level by taking into account
the number and severity of 19 predefined comorbid condi-
tions, and it provides a weighted score, which can be used
to predict short- and long-term outcomes, such as physical
function, hospitalization duration, and mortality rates.69
Wu et al70 found that baseline CCI score was a significant
predictor of survival of RT recipients of any age, including
those 60 years or older; however, among the elderly, this re-
lation between comorbidity and survival was seen only inrecipients of DD kidneys, but, surprisingly, not in recipients
of living donor (LD) kidneys. Heldal et al34 found that CCI
predicts mortality in RT patients aged 60 to 69 years, but
not in those 70 years or older.
Based on data from the United States Renal Data System,
Grams et al71 used logistic regression to develop a prediction
model for post-RT outcomes of ESRD patients 65 years or
older, involving 4 demographic and 15 comorbidity vari-
ables. Application of the model to a Medicare population
of elderly ESRD patients (n = 128 850) identified 11 756 ex-
cellent RT candidates (defined as >87% predicted 3-year
post-RT survival), of whom 76.3% were never actually re-
ferred for RT. It was estimated that 11% of these candidates
would have found a suitable LD had they been offered the
option of RT.
In a similar manner, Dusseux et al,72 using logistic regres-
sion in a cohort of dialysis patients from the French national
registry, developed and then validated in another cohort a
3-year mortality risk score for elderly patients 70 years or
older, based on 14 demographic and comorbidity factors.
Using this score system, they identified a group of patients
with a good prognosis (risk score ≤6 points, ie, ≥65% sur-
vival rate at 3 years), representing 21% of the entire study
group, which could have been considered as appropriate can-
didates for RT.
Evaluation of Frailty
ElderlyRT recipients with a poor functional status, incapa-
ble of performing daily living activities and light exercise,
have a significantly increased short- and intermediate-term
risk of graft loss and mortality.73 Friedman65 believes that
“the patient's activity level and exercise capacity are the best
objective measures of this overall recovery potential (post-RT)”
and that “it is neither reasonable, nor realistic to offer trans-
plantation to an inactive, uninvolved old person for whom
reengagement in life represents excessive optimism.”
Physical frailty is defined as “a medical syndrome with
multiple causes and contributors that is characterized by dimin-
ished strength, endurance, and reduced physiologic function
that increases an individual's vulnerability for developing in-
creased dependency and/or death.”74 Various scales have been
proposed by geriatric specialists to identify and assess the se-
verity of frailty. The phenotypic frailty scale designed by
Fried et al75 consists of 5 items (fatigue, resistance, ambula-
tion, illnesses, and weight loss) and is based on patients'
self-assessment. Frailty is classified by scoring 4 to 5, interme-
diate frailty by scores between 2 and 3, and no frailty by
scores 0 to 1. To reduce subjectivity, this scale has been mod-
ified to include some objective measurements of weakness,
weight loss, and slowwalking speed.76 These 2 scales are pre-
sented in Table 3.5
Frailty is highly prevalent in dialysis patients, and this
prevalence increases with age. According to a study by
Johansen et al,77 44% of dialysis patients younger than
40 years met the criteria for frailty, compared with 78% of
patients 70 years or older. Frailty is a significant predictor
of hospitalization and mortality in dialysis patients52 and
has also been associated with increased risk of delayed graft
function,78 early rehospitalization, and death79 after RT,
among recipients of all ages. The assessment of frailty might
play a role in the selection of elderly patients for RT.80 How-
ever, there is still very limited information about the impact
TABLE 3.
Two phenotypic frailty scales5
A phenotypic frailty scale based
on questions75
A phenotypic frailty scale based on
questions and measurements76
Fatigue. Are you fatigued? Weakness. Decreased grip strength as
measured by a handed dynamometer
Resistance. Are you unable to
climb stairs?
Exhaustion. Measured by responses to
questions about effort and motivation
Ambulation. Are you unable to
walk 1 block?
Slow walking. Measured walking time
to walk 4.5 m
Illnesses. Do you have
≥5 illnesses?
Low physical activity. Determined by
asking about leisure time and activity
Loss of weight. Have you lost
5% of your weight in the
last 6-12 mo?
Shrinking. Unintentional weight loss
≥4.5 kg in the last 12 mo
© 2016 Wolters Kluwer Segall et al e61of frailty on mortality in elderly transplant recipients, and
there are no guidelines indicating at which level of frailty
a patient should be excluded from a waiting list.5 Further
studies of frailty as a predictor of post-RT outcomes are
needed before its routine use in such decision-making can
be recommended.
Evaluation of Psychosocial Issues and Adherence
to Prescriptions
Mild cognitive impairment and dementia are common
among patients with ESRD, affecting 16% to 38% of them,
particularly the elderly. Dementia is associated with high
risks of death, hospitalization, and disability in this popula-
tion.81 However, practice guidelines do not recommend rou-
tine cognitive testing beforeRT, not even in elderly patients.80
Successful RT (in terms of improved long-term survival
and QOL) requires a good cooperation of patients and their
supporters (familymembers, residence nurses) with the trans-
plant team, to ensure adherence to recommended lifestyle,
nutrition, medication, and follow-up visits.65 This adherence
may be considerably affected in elderly patients with cogni-
tive impairment, but also in those with visual or physical
deterioration, depression, social isolation, and/or finan-
cial restraint. It is crucial that such issues are identified
and addressed properly, considering that poor adherence
can contribute to acute rejection episodes, graft loss, and
other complications.
Signs of cognitive deterioration or depression, as well
as previous medical nonadherence, may predict poor ad-
herence after RT. In addition, specific questionnaires can
be used to identify patients who are more likely to be
nonadherent, such as the Basel Assessment of Adherence
to Immunosuppressive Medications Scale or the Theory
of Planned Behaviour instrument; the latter may also help
understanding the reasons of nonadherence and guide in-
terventions to reduce it.5STRATEGIES TO INCREASE ACCESS TO RT FOR
THE ELDERLY
In a retrospective analysis from 2009, which included
54 669 candidates 60 years or older from the SRTRdatabase,
Schold et al82 estimated that 46% of these candidates were
expected to die before receiving a DD RT. The authorsclaimed that this information should be shared with the el-
derly candidates and their caregivers to encourage them to
consider the option of LD RT as a probably more promising
alternative. Indeed, Schaeffner et al83 showed that in the
United States, in ESRD patients aged 60 to 75 years, access
to RT doubled between 1995 and 2006, and this improve-
ment in access was largely due to a 3-fold increase in the
number of both LD and expanded criteria donor (ECD)
RT cases.
To overcome the growing discrepancy between supply and
demand of kidney allografts, ECDs (ie, donor age 60 years or
older or 50 to 59 years and additional comorbidity), as well
as donors after cardiac death, are increasingly used for RT
in many countries.4 Furthermore, a “young-for-young and
old-for-old” strategy (young-for-young particularly in the
United States, and old-for-old in several European countries)
has been implemented in recent years for utility reasons, that
is, to reduce the need for repeat RT in the young and the rate
of allograft loss due to recipient's death in the elderly.4 This
strategy is also thought to be equitable, at least from the per-
spective of the principle of “fair innings,” which maintains
that “patients developing ESRD at younger ages are worse
off than those developing ESRD when older, because they
have had fewer healthy life years.”84 Thus, ECD listing is
particularly advisable for older patients who lack an LD
and in whom a prolonged wait for a standard criteria donor
(SCD) kidney is anticipated.62
Kidneys from elderly donors are associated with an in-
creased risk of rejection when transplanted into younger re-
cipients. However, when older grafts are allocated to older
recipients, this effect is blunted, conceivably because of the
immunosenescence.4 Expanded criteria donor RTwas shown
to yield good results in the elderly in most studies. In a French
study,14 ECD RT in patients 60 years or older was associated
with higher survival rates than remaining on the waiting list
(relative risk [RR], 2.31; P < 0.0001). Using the SRTR data-
base, Rao et al10 confirmed that patients 70 years or older
also have a survival advantage with an ECD kidney (RR,
0.75; 95% confidence interval [95%CI], 0.65-0.86) compared
with nontransplanted waitlisted candidates. In another study
of SRTR data of 145 470 RT patients,37 ECD versus SCD kid-
neys were significant predictors of mortality in patients youn-
ger than 70 years, but not in those 70 years or older, after a
median follow-up of 3.9 years. Hernandez et al,85 based on
UNOS data analysis of about 137 000 transplants, showed
that recipients 70 years or older had comparable outcomes if
they received low-quality kidneys compared with medium-
quality kidneys, as measured by the Kidney Donor Profile
Index; however, very low-quality kidneys had significantly
worse outcomes. In a study of 109 127 patients from a US
national registry, Merion et al86 compared mortality after
ECD RT with that in a standard-therapy group consisting
of SCD recipients and patients staying on dialysis. Overall,
the 3-year RR of mortality was 17% lower for ECD recipi-
ents (RR, 0.83; 95% CI, 0.77-0.90; P < 0.001). For patients
60 years or older, the survival benefit was even greater, with a
22% decrease in mortality (RR, 0.78; 95% CI, 0.68-0.90).
Schold and Meier-Kriesche87 found that patients 65 years
or older had a slightly longer life expectancy if they accepted
an ECD kidney within 2 years of starting dialysis therapy
(5.6 years), rather than waiting 4 years to receive a SCD
(5.3 years) or a LD (5.5 years) kidney.
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cation of donor organs in 8 European countries (Austria,
Belgium, Croatia, Germany, Hungary, Luxembourg, the
Netherlands, and Slovenia)—introduced in 1999 the Euro-
transplant Senior Program (ESP) to offer elderly candidates
rapid access to transplantation. The ESP preferentially allo-
cates kidneys from donors 65 years or older locally or over a
narrow geographic area to unsensitized recipients 65 years
or older. A report of the program's first 5 years88 compared
the ESP group (old to old [O/O]) to 2 groups allocated via
the standard Eurotransplant Kidney Allocation System
with either old donor age (old to any [O/A], donor age
≥65 years) or old recipient age (any to old, [A/O], recipient
age 60-64 years). Patients from ESP had worse 5-year sur-
vival than A/O patients in Eurotransplant Kidney Alloca-
tion System (60% vs 74%, P < 0.001) and worse 5-year
graft survival (47% vs 64%, P <0.001). On the other hand,
the authors found that ESP led to significantly shorter
waiting time (3.55 years in ESP vs 4.64 years in A/O;
P <0.001), as well as shorter cold ischemia time and less
delayed graft function for the elderly recipients. Also, the
number of older grafts accepted for RT significantly in-
creased and the discard rates decreased since the initiation
of ESP, suggesting that more elderly patients could be
transplanted under ESP. Considering that RTconfers a sur-
vival benefit compared to dialysis, the authors believe that
the trade-off might be warranted.88 Rose et al89 compared
5-year outcomes in the ESP and United States Renal
Data System. They found that among European recipients
65 years or older, patient survival exceeded graft survival,
and ECD recipients returned to dialysis for an average of
5.2 months after transplant failure, whereas among US re-
cipients 60 years older, graft survival exceeded patient sur-
vival. The average difference in patient survival at 10 years
in elderly recipients in the United States with an ECD ver-
sus non-ECD transplant was only 7 months.
However, not all studies reported benefits of this O/O
strategy. Veroux et al90 showed that patients 65 years or
older who received kidneys from DD also 65 years older
had worse survival rates than patients of similar age remain-
ing on the waiting list. Such results suggest that maybe there
should be a donor age upper limit and/or a minimum quality
standard for ECD kidneys to be accepted for RT. In some
cases, an alternative to discarding is to transplant 2 ECD kid-
neys that are declined for use as single organs due to poor
function; however, this requires more extensive and risky sur-
gery, which can be problematic for elderly patients.65
Another very important strategy to increase RT in elderly
candidates is to promote living donation.24 The propor-
tion of LD recipients 65 years or older doubled in the
United States from 6.8% in 2001 to 13.7% in 2011.66 Several
studies10,91-93 showed that LD RTwas associated with better
graft survival rates than DD RT in elderly recipients, as well
as in younger ones. With respect to donor age, an analysis of
UNOS data by Gill et al94 demonstrated that in recipients
60 years or older RT from LDs 55 years or older have similar
3-year graft survival (83.4 vs 85.7%;P =NS) and patient sur-
vival rates (87.4 vs 88.4%; P =NS) as RT from younger LDs,
and that kidneys from LDs 65 years or older showed graft
survival rates comparable to deceased SCD and superior to
deceased ECD transplants. Furthermore, in an analysis of
SRTR data, Berger et al95 found that graft survival forkidneys fromLDs 70 years or olderwas similar to that of kid-
neys from deceased SCDs 50 to 59 years.CONCLUSIONS AND RECOMMENDATIONS
1. For selected elderly ESRD patients, RTwas shown to be su-
perior to dialysis in terms of patient survival and, possibly,
QOL and cost-effectiveness.
2. Death-censored graft survival is similar or even better in el-
derly RT recipients, as compared with younger counterparts.
3. RT appears to be safe in the elderly, if candidates are care-
fully selected. Given the senescence of the immune system,
the use of lower doses of immunosuppressive drugs is likely
to minimize side effects, without excess rejections; how-
ever, specific options need to be tested in randomized
controlled trials.
4. Virtually all guidelines recommend that patients should not
be deemed ineligible for RT based on age alone.
5. A short life expectancy generally precludes RT; however,
this principle may be difficult to interpret and apply in clin-
ical practice, because there is no general consensus over the
definition of “short,” and it is often unclear how life expec-
tancy can be estimated.
6. The evaluation of elderly patients for RT basically has the
same objectives and uses the samemethods as for all RTcan-
didates. This involves thorough medical and psychosocial
assessment. However, the existing guidelines contain very
few specific recommendations on the criteria to use for
selecting elderly candidates for RT.
7. Many guidelines recommend that elderly potential candi-
dates for RTshould be screenedmore aggressively andmore
frequently for cardiovascular disease and cancer. Significant
age-related comorbidities could be considered as relative
contraindications to RT. However, the specific investigation
methods and time intervals to be used, as well as criteria
for exclusion, are still poorly defined and not supported
by evidence.
8. For cardiac evaluation, noninvasive stress testing may be
considered in asymptomatic patients 60 years or older
who also have at least 2 other risk factors for coronary ar-
tery disease, although there is little evidence to support
this recommendation.
9. With regard to malignancy, age-appropriate screening as in-
dicated for the general population should be performed for
RT candidates, in the absence of specific guidelines for these
patients. This usually includes colonoscopy in patients
50 years or older and mammogram in women 40 years
or older.
10. Several comorbidity scores can predict post-RT mortal-
ity and might be used to guide decision-making on eligi-
bility. However, such scores should be validated in
additional studies.
11. The assessment of frailty might also play a role in the selec-
tion of elderly patients for RT. Various scales have been pro-
posed in this regard. However, there is still very limited
information about the impact of frailty on mortality in el-
derly RT recipients, and there are no guidelines indicating
at which level of frailty (if any) a patient should be excluded
from a waiting list.
12. Psychosocial issues, including cognitive deterioration, de-
pression, social isolation, and financial problems, are com-
mon in elderly patients and may have a significant impact
on compliance to prescriptions and, ultimately, on patient
and graft outcomes. Therefore, these issues should be
assessed prior to RTwaitlisting, as well as thereafter. Specific
questionnaires can be used to identify patients who aremore
likely to be nonadherent.
© 2016 Wolters Kluwer Segall et al e6313. Elderly patients should be encouraged to consider ECD and
LD, as alternatives to deceased SCD, in order to increase
their chances of access to RT. It has been demonstrated that
ECD RT in patients 60 years or older is associated with
higher survival rates than remaining on dialysis, while LD
RT is superior to all other options. Systems like the ESP—
which offers preferential allocation of ECDs to this age
group—should be promoted.
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